TruScreen Group (TRU) H2 2025 earnings summary

Executive summary

• Achieved significant clinical and regulatory milestones, including WHO and UNITAID guideline inclusion and new market entries in China, Vietnam, India, Indonesia, Uzbekistan, and Mexico.

• Signed a strategic MOU with Hangzhou Dalton Bioscience to expand product offerings and distribution, starting with India.

• Launched a 5-year, 260,000-women screening program in Ho Chi Minh City and expanded distribution in key emerging markets.

• Raised $2.3 million via private placement and $1.67 million through a Share Purchase Plan post year-end to support growth.

• Recognized by Health Startups 2024 as a top 6 global healthcare company impacting women's health.

Financial highlights

• FY2025 sales were NZ$1.71M, down 18.7% year-over-year; total revenue was NZ$2.11M, down 15.7%.

• Net loss increased to NZ$2.24M from NZ$2.05M year-over-year (9.4% higher).

• Cash outflow from operating activities was NZ$2.29M, up 12.6% year-over-year.

• Cash and cash equivalents at year-end were NZ$365K, down 86.6% from the prior year.

• Basic and diluted loss per share was (0.41) cents, compared to (0.49) cents in the prior year.

Outlook and guidance

• Anticipates continued revenue growth in China in FY2026, with expansion into six key provinces and the private health sector.

• Vietnam expected to become the second largest market in FY2026, with a major public screening program underway.

• Strategic alliance with DaltonBio expected to drive growth in India and other emerging markets.

• Ongoing regulatory approvals and new distributor appointments to support further international expansion.